Loading stock data…
$76.06-1.52 (-1.96%)
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
Dianthus Therapeutics, Inc. in the Healthcare sector is trading at $76.38 with a market capitalization of $6.0B. Wall Street consensus targets $140.80 (15 analysts), implying a +84.4% move over the next 12 months. The stock is currently 35% below its 52-week high of $117.88, remaining 7.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 7 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $761,000↑ | $463,000↑ | $284,000↓ | $396,000↑ | $193,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$61.48M↓ | -$46.53M↑ | -$69.54M↓ | -$40.29M↓ | -$34.93M |
| Net Income | -$50.22M↓ | -$40.83M↑ | -$64.43M↓ | -$36.77M↓ | -$31.63M |
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended...